Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer

Lu, Shun; Zhang, Wei; Wu, Lin; Wang, Wenxiang; Zhang, Peng; Investigators, Neotorch; Fang, Wentao; Xing, Wenqun; Chen, Qixun; Yang, Lin; Mei, Jiandong; Tan, Lijie; Sun, Xiaohong; Xu, Shidong; Hu, Xiaohua; Yu, Guohua; Yu, Dongliang; Yang, Nong; Chen, Yuping; Shan, Jinlu; Xing, Ligang; Tian, Hui; Zhang, Xun; Zhou, Ming; Fang, Haohui; Wu, Guowu; Liu, Yunpeng; Ye, Minhua; Cao, Lejie; Jiang, Jie; Li, Xingya; Zhu, Liangming; Li, Shanqing; Kang, Mingqiang; Zhong, Aihong; Chen, Keneng; Wu, Nan; Sun, Qian; Ma, Haitao; Cai, Kaican; Wang, Changli; Lin, Gen; Zhu, Kunshou; Zhang, Yu; Zhang, Xiaochun; Hu, Hong; Zhang, Wengang; Chen, Jun; Yang, Zhixiong; Hang, Xiaosheng; Hu, Jian; Huang, Yunchao; Zhang, Zhiye; Zhang, Lumin; Zhang, Liwei; Liu, Lunxu; Lin, Dongmei; Zhang, Jie; Chen, Gang; Li, Yuan; Zhu, Lei; Wang, Weihua; Yu, Wenbo; Cao, Dezhen; Keegan, Patricia; Yao, Sheng

doi:10.1001/jama.2023.24735

Public

Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer

Shared by NobleBlocks on Jan 16, 2024 • 12:00 AM UTC

Authors:

Shun Lu

Wei Zhang

Lin Wu

Abstract

Importance Adjuvant and neoadjuvant immunotherapy have improved clinical outcomes for patients with early-stage non–small cell lung cancer (NSCLC). However, the optimal combination of checkpoint inhibition with chemotherapy remains unknown. Objective To determine whether toripalimab in combination w...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!